August 10, 2016
Astellas Pharma said on August 9 that it has submitted a new drug application in Japan for extended-release tablets of quetiapine fumarate (development code: FK949E) for the treatment of depressive symptoms associated with bipolar disorder. The once-daily quetiapine tablets, licensed...read more